Myrelez (Lanreotide Acetate)

Lanreotide Acetate, the active ingredient in Myrelez, is a somatostatin analog presented as a sterile solution for subcutaneous injection, typically supplied in a prefilled syringe. It is used to treat acromegaly by lowering excess growth hormone and to provide symptomatic control of gastroenteropancreatic neuroendocrine tumors in adult patients.

GNH USA supplies Myrelez as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, ensuring quality‑controlled distribution and regulatory compliance and patient safety across multiple global markets.

Myrelez, a somatostatin analog used in hormone‑secreting tumor management, is indicated for: Acromegaly: reduces excess growth hormone levels and improves associated clinical signs. Gastroenteropancreatic neuroendocrine tumors (GEP‑NET): provides symptomatic control of hormone‑related flushing, diarrhoea and abdominal pain. Carcinoid syndrome: alleviates flushing, diarrhoea and abdominal cramping caused by peptide hormone secretion in neuroendocrine tumors. Hormone‑secreting pituitary adenoma: helps lower hormone output and may reduce tumor size in selected patients.

Adverse reactions reported with Myrelez are categorized by frequency.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Diarrhoea: increased frequency of loose stools. - Nausea: transient feeling of sickness. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Gallstone formation: development of biliary calculi. - Acute pancreatitis: inflammation of the pancreas presenting with severe abdominal pain. - Severe allergic reaction: anaphylaxis or angioedema requiring immediate medical attention.

Before initiating Myrelez, consider the following precautions. - Monitor blood glucose: assess for hyperglycaemia, especially in diabetic patients. - Evaluate gallbladder status: patients with gallstones may require monitoring. - Screen for pancreatitis: discontinue if signs of acute pancreatitis appear. - Assess cardiac function: use cautiously in patients with known arrhythmias. - Pregnancy and lactation: prescribe only if potential benefit justifies the risk to the fetus or infant. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Myrelez may interact with other medicines; notable interactions include:

Major Interactions (Avoid): - Concomitant use with other somatostatin analogs: may increase risk of hormonal suppression. - Cyclosporine: lanreotide can raise cyclosporine concentrations, increasing nephrotoxicity risk. - Insulin or oral hypoglycaemic agents: may alter glucose control, requiring dose adjustments.

Moderate Interactions (Monitor Closely): - Octreotide: additive somatostatin effects may enhance adverse events. - Dopamine agonists (e.g., cabergoline): may affect endocrine balance and require monitoring.